Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.

@article{Kita2014EffectsOB,
  title={Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.},
  author={Mariko Kita and Robert J Fox and J. Theodore Phillips and Michael Hutchinson and Eva Kubala Havrdov{\'a} and Sujata P Sarda and Sonalee S Agarwal and Jessica S. T. Kong and Annie Zhang and Vissia Viglietta and Sarah I. Sheikh and Emily Seidman and Katherine T. Dawson},
  journal={Multiple sclerosis},
  year={2014},
  volume={20 2},
  pages={253-7}
}
Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing-remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-9 of 9 references

Similar Papers

Loading similar papers…